Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GlaxoSmithKline and XenoPort receive FDA approval for Horizant™
GSK & XNPT announced that the FDA has approved Horizant for the treatment of moderate-to-severe primary Restless Legs Syndrome in adults.
-
GSK publishes payments for research consulting and advising by US healthcare professionals
GSK published a list of payments for clinical research studies led by U.S. healthcare professionals, for the discovering of new medicines.
-
GlaxoSmithKline confirms Pronova BioPharma reaches agreement with Apotex regarding Lovaza™ US patent litigation
GSK confirmed that Pronova entered into an agreement with Apotex to settle their patent litigation in the United States related to Lovaza.
-
GSK and Valeant receive European authorisation for Trobalt (retigabine)
GSK & VRX announced, EC has granted marketing authorisation for Trobalt (retigabine) as an add-on treatment of partial onset seizures.
-
GSK publishes 2010 Corporate Responsibility Report
In its CRR, GSK reiterated its commitment to building its business on strong values and ethical standards.
-
GSK statement on Avodart™ (dutasteride) for prostate cancer risk reduction
GSK announced it will no longer pursue global approval for the use of Avodart (dutasteride) to reduce the risk of prostate cancer.
-
GSK launches London 2012 initiative with King’s College London to inspire young people into science careers
Scientists in Sport programme designed to inspire young people published a study that 8/10 secondary school pupils are worried about work.
-
GSK supports recovery efforts to help those affected by the Japan earthquake
As a result of the Tohoku Kanto Earthquake and tsunami GSK is supporting the ongoing relief efforts and pharmaceutical donation needs.
-
GSK announces positive topline results of Phase lll study of IPX066 in advanced Parkinson’s disease
GSK announced results of the PD Phase III study by Impax Pharma, of IPX066 versus IR CD-LD patients experiencing motor fluctuations.
-
GlaxoSmithKline and Tolerx announce phase III DEFEND-1 study of otelixizumab in type 1 diabetes did not meet its primary endpoint
GSK and Tolerx announced Phase III DEFEND-1 study of otelixizumab did not meet the PFS at month 12 in patients with type 1 diabetes.
-
GlaxoSmithKline and Human Genome Sciences announce FDA approval of Benlysta® (belimumab) for the treatment of systemic lupus erythematosus
GSK & HGS announced that the FDA has approved Benlysta for the treatment of active, autoantibody-positive SLE who are receiving therapy.
-
GlaxoSmithKline plc appoints two Non-Executive Directors to its Board (1)
GSK announces, Ms. Judy Lewent and Ms. Stacey Cartwright have been appointed as Non-Executive Directors and will join the Board from 1/4/11.
-
Regulatory update: Nimenrix® (MenACWY vaccine)
GSK submitted a MAA to EMA for Nimenrix, active immunisation against meningococcal diseases caused by Neisseria meningitidis serogroups.
-
GSK outlines new plan to drive recruitment and attract graduate talent in the UK
GSK outlined new plans to encourage talented students graduating from UK universities to consider pursuing a career within the company.
-
Reward for charities bridging gaps in health care provision
Ten UK charities have each won £25,000 in recognition of their outstanding contribution to improving health care, part of GSK IMPACT Awards.
-
World’s first everyday fluoride toothpaste with NovaMin® technology that can repair sensitive teeth
GlaxoSmithKline Consumer Healthcare today announced a breakthrough in dental care with the launch of new Sensodyne Repair & Protect.
-
David Redfern appointed as new Chairman of ViiV Healthcare
GSK, ViiV & Pfizer announced the appointment of David Redfern as the new Chairman of the Board for ViiV Healthcare with effect from 1/4/11.
-
GSK European regulatory update on Pandemrix™ (1)
CHMP concludes that data are insufficient to establish a causal relationship between Pandemrix and narcolepsy.
-
First African country introduces GSK’s pneumococcal vaccine through innovative financing mechanism
GSK announced the incorporation of its pneumococcal vaccine into the Kenyan national immunisation programme.
-
GlaxoSmithKline moving to new building at Philadelphia Navy Yard
GSK & LRY announced they signed a 15.5-year lease for a new building to be developed by Liberty Property Trust and Synterra Partners.
